|
Argeris (Jerry) N. Karabelas, Ph.D. served as interim chief executive officer for NitroMed from March 2006 to January 2007. He joined our board of directors in January 2002 and became chairman in August 2003. Since November 2001, Dr. Karabelas has been a partner in Care Capital LLC, a life sciences investment firm. From June 2000 to November 2001, Dr. Karabelas served as chairman of Novartis BioVentures Ltd., a private equity firm that he co-founded and that is affiliated with Novartis, AG a pharmaceutical company. Dr. Karabelas also served as Head of Healthcare and Chief Executive Officer of Worldwide Pharmaceuticals for Novartis, AG from January 1998 to July 2000. Prior to Novartis, Dr. Karabelas held leadership positions at SmithKline Beecham from 1993 through 1998 including: Executive Vice-President, Pharmaceuticals; President, North American Pharmaceuticals; and Vice President of U.S. Marketing. He is a member of the Visiting Committee for Health Sciences and Technology at Massachusetts Institute of Technology. Dr. Karabelas is Chairman of the Board for Human Genome Sciences, Inc., Inotek, Inc., Renovo Ltd., SkyePharma PLC and Vanda Pharmaceuticals. He also serves as a director for Acura Pharmaceuticals, Inc., Anadys Pharmaceuticals, Inc. and the International Partnership on Microbicides. Dr. Karabelas holds a Ph.D. in pharmacokinetics from the Massachusetts College of Pharmacy | 